CANBERRA, Australia, May 29, 2012 /PRNewswire-Asia/ -- Australia's leading science agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), has been granted

LONDON, December 12, 2011 /PRNewswire/ -- Silence Therapeutics plc [http://www.silencetherapeutics.com ] (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference

In a paper published in the October 2011 issue of Experimental Biology and Medicine, a team of researchers at Columbia University Medical Center led by Stephen Tsang, MD, Ph.D have achieved temporary functional preservation of photoreceptors in a mouse model for retinitis pigmentosa (RP) using novel bipartite gene therapy.

LONDON, April 27, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics Plc (AIM: SLN), a leading international RNAi therapeutics company, today announces its results for the year ended 31 December 2010. Analyst Conference Call: There will be a call for analysts today at 14:30 BST / 09:30 ET.

In its continuing support of the DECIPHER Project—an open access platform for genome-wide RNAi screening and analysis, Cellecta released the 3rd DECIPHER shRNA Expression Library Module which targets an additional 5,000 human genes enabling researchers to now analyze the functionality of over 15,000 human genes for various biological processes with all three human modules. Mountain View, CA (PRWEB) February 25, 2011 Today, Cellecta, Inc.